Members of the state’s Tax and Fiscal Policy Committee voted 12-0 on Tuesday morning to stall legislation that would give central Indiana voters the ability to choose if they want to pay higher taxes for expanded mass transit.
Over his four-year tenure, Lee Rosenthal helped WXIN-TV Channel 59 more than double the airtime it devotes to news.
Johnson & Johnson won approval for the first in a new family of diabetes drugs, giving the New Jersey-based drugmaker an edge over Eli Lilly and Co. and other rivals developing similar medicines. On Friday, the U.S. Food and Drug Administration cleared the drug, known as canagliflozin, to treat adults with Type 2 diabetes. It will be sold under the brand name Invokana and may generate as much as $800 million in annual sales, Tony Butler, an analyst at Barclays Plc in New York, told Bloomberg News. The drug is part of a class called SGLT2 inhibitors, which expel sugar in the urine after the kidneys filter it out of the blood. Similar drugs are being developed by Indianapolis-based Lilly, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co. and AstraZeneca plc.
Medical claims will rise more than 67 percent—the third-highest rate in the nation—for Indiana residents buying individual health insurance policies under President Barack Obama's health care overhaul, according to a study by the Society of Actuaries. The projected increase is partly due to sicker people joining the insurance pool. The study says most states will see increases, and assumes every state will expand its Medicaid program, but that's uncertain in Indiana. The Obama administration says the study ignores subsidies to help with premiums. Middle-class households can buy subsidized insurance in new marketplaces Oct. 1. The report doesn't cover employer plans.
Dow AgroSciences LLC will formally open a 175,000-square-foot building on April 10, which will be home to 200 researchers working on plant biotechnology. Dow AgroSciences first announced the $340 million expansion in March 2010, saying it would lead to an additional 577 high-paying jobs over the following five years. The company, which is a subsidiary of Michigan-based Dow Chemical Co., said most of the positions would pay $65,000 to $95,000 annually. Dow AgroSciences had sales last year of $6.4 billion, and produced earnings before taxes, interest, depreciation and amortization of $977 million.
A pack of conferencing critics had their eyes opened to Indy’s arts pleasures. In turn, they opened my eyes to some things I shouldn’t take for granted.
Often with great pride, elected officials and those seeking elective office exclaim that Indiana is a paragon of fiscal probity and that bountiful state reserves demonstrate the caliber of Hoosier leadership.
I have a favorite excuse for failure in business: “It takes money to make money.”
The athletic footwear and clothing company said Thursday that its fiscal fourth-quarter earnings dropped 18 percent due to lackluster sales at stores open at least a year.
Hoosiers are often thought of as resistant to change (daylight-saving time, anyone?).
Fresh analysis released last month on the economic impact of the Indianapolis Motor Speedway and the satellite industries attracted by its location in Indiana make it clear the General Assembly is on the right track in moving legislation to bolster the track and the jobs it helps create.
Indianapolis is a long way from reaching its potential. Yes, we have advantages with cost of living (compared to both coasts), and great professional sports franchises and an array of quality cultural institutions like the Indianapolis Symphony Orchestra and The Children’s Museum of Indianapolis, and many more.
No one pays attention to a sentence buried in the middle of a recent news story out of Indiana University.
The iKnow system will be introduced alongside other changing features with the launch of ChaCha 2.0, which will likely happen in early April, company founder Scott Jones said.
Indiana real estate investment trusts are hitting new highs while outpacing the bull market and their peers in the usually hardy and suddenly hot sector.
Eli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted the value of their compensation packages 3 percent to 8 percent. John Lechleiter, CEO of the Indianapolis-based drugmaker, saw his overall compensation reduced 10.7 percent because the calculated value of his pension fell. But excluding that on-paper reduction, the actual compensation Lechleiter received for 2012 rose 3.6 percent to $10.2 million. His salary and stock award were unchanged from 2011, but his bonus rose 13.6 percent to nearly $3 million. Chief Financial Officer Derica Rice received a modest increase in salary and a larger bonus. His overall compensation, excluding the pension adjustment, rose 3.3 percent to $5.2 million. Jan Lundberg, the president of Lilly Research Laboratories, enjoyed increases in his salary, stock award and bonus, which boosted his overall pay 8.3 percent to $4.5 million, excluding any pension adjustment.
Hospital officials praised Indiana's medical savings accounts but some consumer advocates panned them March 20 during a public hearing on Gov. Mike Pence’s plan to use the Healthy Indiana Plan to expand Medicaid in Indiana, according to the Associate Press. The Indiana Hospital Association and officials from hospitals around the state said the Healthy Indiana Plan would reduce the amount of indigent care they must provide to uninsured patients. But critics noted HIP isn't available to everyone, and even when it is, it can prove too costly for some low-income Indiana residents needing medical care. "I do not believe it will do what we need to do to cover people," said Rep. Sue Errington, D-Muncie. Pence has proposed using HIP to complete a Medicaid expansion for Indiana residents earning up to 138 percent of the federal poverty level. That's a sliding scale that includes $15,856 for a single individual or $32,499 for a household of four. If the Centers for Medicaid and Medicare Services approves Pence's proposal, it could provide coverage for as many as 400,000 low-income residents. If CMS rejects it, it could end coverage for about 40,000 residents already enrolled in HIP. A decision must to be made by June, six months before the state's current waiver expires. Also, Pence has said he might not sign off on the expansion using HIP even if CMS approves it.
Boehringer Ingelheim GmbH and Eli Lilly and Co. filed for FDA approval of a new anti-diabetes medicine, the two companies announced Monday. The drug, empagliflozin, is known as an SGLT2 inhibitor and fights Type 2 diabetes by removing excess glucose through a patient’s urine by blocking the re-absorption of glucose in the kidney. Several large pharmaceutical companies are trying to bring an SLGT2 inhibitor drug to market. In January, New Jersey-based Johnson & Johnson, won the backing of an FDA advisory panel for its drug, called canagliflozin. Other companies in the SGLT2 race are New York-based Bristol-Myers Squibb Co. and United Kingdom-based AstraZeneca plc. Lilly is helping to develop and commercialize empagliflozin, which was discovered by Germany-based Boehringer Ingelheim. The drug is one of five that Lilly hopes to submit to the U.S. Food and Drug Administration this year.
Indianapolis startup MaxTradein has expanded its operations to Cincinnati, taking the first step in what its founders hope will be a national rollout.
Already one of the most highly regarded CEOs in Indiana and in his industry, David Simon of Simon Property Group now is keeping company with the likes of Warren Buffett, Amazon’s Jeff Bezos and Larry Page of Google.
Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for years, steep price declines.
Analysts remain bullish on the Indianapolis-based email marketing firm despite its sluggish stock price, due to the company’s strong revenue and aggressive investment in research and acquisitions.
We the people keep demanding more of them without budgeting enough to build or maintain them.
Years ago, the high-tech company that drove me closest to the edge of madness was Microsoft. That firm treated its customers as if they were lucky to have computers. But for sheer frustration, I think Google tops Microsoft.
